Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT and SBRT Combined With PD-1 Inhibitors in Advanced NSCLC
NCT05615142Phase 1Active, not recruiting
- Sponsor
- Sichuan University
- Start
- Dec 2021
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Sichuan University. Primary endpoint: Adverse Events and Dose Limiting Toxicities at 48 months. Started Dec 2021; status: active, not recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05615142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05615142.